| Immune checkpoint association |
| durvalumab plus tremelimumab |
| mNSCLC - L2 - adenocarcinoma cell | |
| mNSCLC - L2 - all population 5 | |
| mNSCLC - L2 - EGFR high | |
| mNSCLC - L2 - EGFR mutant 1 | |
| mNSCLC - L2 - EGFR wild type | |
| mNSCLC - L2 - KRAS mutant | |
| mNSCLC - L2 - KRAS wild type | |
| mNSCLC - L2 - PDL1 negative 1 | |
| mNSCLC - L2 - PDL1 positive 7 | |
| non squamous cell - mNSCLC - L2 | |
| non squamous - mNSCLC - L2 - all population 1 | |
| non squamous - mNSCLC - L2 - EGFR mutant | |
| non squamous - mNSCLC - L2 - PDL1 positive | |
| non squamous - mNSCLC - L2 - wild type (WT) | |
| squamous cell - mNSCLC - L2 | |
| squamous - mNSCLC - L2 - all population 1 | |
| squamous - mNSCLC - L2 - PDL1 positive | |